The effective shelf gives Akari an immediate-at-the-ready $25M capital backstop. Investors should watch for any 8-K announcing an initial draw, as that would signal both fresh cash and immediate dilution. With ~$0.5M cash, the company likely triggers a draw soon.
Price Chart
Executive Summary
This is a notice of effectiveness (EFFECT) for a resale shelf (File No. 333-289962) covering up to 2.5 million ADSs that may be issued to White Lion Capital under a purchase agreement for up to $25 million. While the company gets no direct proceeds from the resale, the effectiveness unlocks the company's ability to draw down up to $25 million from White Lion at its discretion — a critical liquidity source for a $19M market-cap biotech with only ~$0.5M cash. The filing is neutral in sentiment because the shelf-registration is routine procedural, but the $25 million backstop is a notable potential liquidity positive.
Key Facts
- EFFECT for File No. 333-289962 (S-1/A filed June 26, 2026) declared effective on July 7, 2026 by SEC.
- Registration covers up to 2,500,000 ADSs (each representing 80,000 ordinary shares) for resale by White Lion Capital LLC.
- Company may draw up to $25,000,000 in gross proceeds from White Lion under the August 29, 2025 Purchase Agreement, at its discretion.
- If no draw is made in 180 days post-effectiveness, the company will issue 6,361 commitment ADSs valued at $75,000 to White Lion.
- ADSs trade on Nasdaq under AKTX; closing price on June 25, 2026 was $9.52 per ADS.
- Company's cash position was approximately $0.5 million as of the prior S-3 filing analysis.
Financial Impact
Up to $25M potential gross proceeds from White Lion Capital drawdown; no immediate cash inflow upon effectiveness.
Risk Factors
- Any draw under the Purchase Agreement will be highly dilutive — each ADS represents 80,000 ordinary shares, and the total ordinary share count is astronomical.
- If no draw occurs within 180 days, the company still issues $75K in commitment ADSs to White Lion, a trivial cost.
- The selling stockholder (White Lion) is an underwriter; aggressive resale may pressure the ADS price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002205 |
| Document: 9999999995-26-002205-index.html | 9999999995-26-002205 |
| Document: 9999999995-26-002205.txt | 9999999995-26-002205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.63 (+1.19%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.63 (+43.14%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.63 (−46.31%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.63 (+26.71%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.63 (−65.40%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.63 (+57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers